TY - JOUR
T1 - Second breast cancer
T2 - recurrence score results, clinicopathologic characteristics, adjuvant treatments, and outcomes—exploratory analysis of the Clalit registry
AU - Shachar, Shlomit S.
AU - Leviov, Michelle
AU - Yerushalmi, Rinat
AU - Drumea, Karen
AU - Tokar, Margarita
AU - Soussan-Gutman, Lior
AU - Bareket-Samish, Avital
AU - Sonnenblick, Amir
AU - Ben-Baruch, Noa
AU - Evron, Ella
AU - Gal-Yam, Einav Nili
AU - Paluch-Shimon, Shani
AU - Bar-Sela, Gil
AU - Goldvaser, Hadar
AU - Stemmer, Salomon M.
N1 - Publisher Copyright:
© 2023, Springer Nature Limited.
PY - 2023/12
Y1 - 2023/12
N2 - Data on using the 21-gene Recurrence Score (RS) testing on second breast cancer (BC; second primary or local recurrence) are lacking. This cohort study examined patients with first and second BC, who underwent 21-gene testing both times. It included a ‘study-cohort’ (60 N0/N1mi/N1 ER + HER2‒ BC patients with ≥2 RS results >1 year apart) and a ‘general 21-gene-tested BC-cohort’ (2044 previously described N0/N1mi/N1 patients). The median time between the first and second BC was 5.2 (IQR, 3.1–7.1) years; the second BC was ipsilateral in 68%. Patient/tumor characteristics of the first- and second-BC in the ‘study-cohort’ were similar, except for the RS which was higher in the second BC (median [IQR]: 23 [17–30] vs 17 [14–22], p < 0.001). Overall, 56 patients had follow-up data, of whom 5 experienced distant recurrence (2 RS 11–25 patients and 3 RS 26–100 patients). Studies exploring the prognostic utility of the RS in this setting are warranted.
AB - Data on using the 21-gene Recurrence Score (RS) testing on second breast cancer (BC; second primary or local recurrence) are lacking. This cohort study examined patients with first and second BC, who underwent 21-gene testing both times. It included a ‘study-cohort’ (60 N0/N1mi/N1 ER + HER2‒ BC patients with ≥2 RS results >1 year apart) and a ‘general 21-gene-tested BC-cohort’ (2044 previously described N0/N1mi/N1 patients). The median time between the first and second BC was 5.2 (IQR, 3.1–7.1) years; the second BC was ipsilateral in 68%. Patient/tumor characteristics of the first- and second-BC in the ‘study-cohort’ were similar, except for the RS which was higher in the second BC (median [IQR]: 23 [17–30] vs 17 [14–22], p < 0.001). Overall, 56 patients had follow-up data, of whom 5 experienced distant recurrence (2 RS 11–25 patients and 3 RS 26–100 patients). Studies exploring the prognostic utility of the RS in this setting are warranted.
UR - http://www.scopus.com/inward/record.url?scp=85173977510&partnerID=8YFLogxK
U2 - 10.1038/s41523-023-00586-3
DO - 10.1038/s41523-023-00586-3
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 37775723
AN - SCOPUS:85173977510
SN - 2374-4677
VL - 9
JO - npj Breast Cancer
JF - npj Breast Cancer
IS - 1
M1 - 79
ER -
